Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
5191124
Reference Type
Journal Article
Title
[Estimating Permissible Intake Level for Endosulfan Using Benchmark Dose Based on Reproductive Toxicity]
Author(s)
Lee, H; Yoon, E; Yum, YN; Hwang, MS; Yang, KH; Shin, HS
Year
2002
Is Peer Reviewed?
0
Journal
Journal of Toxicology and Public Health
ISSN:
1226-8399
Issue
1
Page Numbers
65-71
Language
Korean
Abstract
A benchmark dose (BMD) approach has been evaluated as a replacement for the traditional NOAEL methodology currently being used to assess the noncancer effects of toxicants. The endocrine disrupting effect of endosulfan which showed decrement of sperm count and testicular testosterone level in animals, was currently reported. The amount of endosulfan used as pesticide in the country has been continuously increased. The aim of this study was to suggest the permissible intake level (PIL), corresponding to Acceptable Daily Intake (ADI), based on endocrine disrupting effect using BMD. Various animal data were collected by consideration of critical effect showing endocrine disruption and an animal data for reproductive toxicity was selected. The Power model from BMD software for induction BMD10 having meaning which is the dose at the 95% lower confidence limit on a 10% response was used due to that the form of selected dose-response animal data was continuous data. The BMD10 was estimated to be 0.393 mg/kg/day based on reproductive toxicity showing decrement of sperm count. The permissible intake level (PIL) was calculated by dividing the BMD10 by the uncertainty factors of 100 with consideration of from animal to human and human variability. The PIL as 0.004 mg/kg/day was compared with traditional ADI as 0.006 mg/kg/day based on the incidence of marked progressive glomerulonephrosis and blood vessel aneurysms in males.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity